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Abstract
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients
with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR)
of 10-15%. We conducted a single arm phase II study to investigate the feasibility and efficacy of addition of
bevacizumab and oxaliplatin to preoperative standard RCT with capecitabine.
Methods: Eligible patients had LARC (cT3-4; N0/1/2, M0/1) and were treated with preoperative RCT prior to
planned surgery. Patients received conventionally fractionated radiotherapy (50.4 Gy in 1.8 Gy fractions) and
simultaneous chemotherapy with capecitabine 825 mg/m
2 bid (d1-14, d22-35) and oxaliplatin 50 mg/m
2 (d1, d8,
d22, d29). Bevacizumab 5 mg/kg was added on days 1, 15, and 29. The primary study objective was the pCR rate.
Results: 70 patients with LARC (cT3-4; N0/1, M0/1), ECOG < 2, were enrolled at 6 sites from 07/2008 through 02/
2010 (median age 61 years [range 39–89], 68% male). At initial diagnosis, 84% of patients had clinical stage T3, 62%
of patients had nodal involvement and 83% of patients were M0. Mean tumor distance from anal verge was
5.92 cm (± 3.68). 58 patients received the complete RCT (full dose RT and full dose of all chemotherapy). During
preoperative treatment, grade 3 or 4 toxicities were experienced by 6 and 2 patients, respectively: grade 4 diarrhea
and nausea in one patient (1.4%), respectively, grade 3 diarrhea in 2 patients (3%), grade 3 obstipation, anal abscess,
anaphylactic reaction, leucopenia and neutropenia in one patient (1.4%), respectively. In total, 30 patients (46%)
developed postoperative complications of any grade including one gastrointestinal perforation in one patient (2%),
wound-healing problems in 7 patients (11%) and bleedings in 2 patients (3%). pCR was observed in 12/69 (17.4%)
patients. Pathological downstaging (ypT <cT and ypN ≤ cN) was achieved in 31 of 69 patients (44.9%). All of the 66
operated patients had a R0 resection. 47 patients (68.1%) underwent sphincter preserving surgery.
Conclusions: The addition of bevacizumab and oxaliplatin to RCT with capecitabine was well tolerated and did not
increase perioperative morbidity or mortality. However, the pCR rate was not improved in comparison to other
trials that used capecitabine or capecitabine/oxaliplatin in preoperative radiochemotherapy.
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Preoperative radiochemotherapy (RCT) with 5-fluorouracil
(5-FU) or capecitabine is the standard of care in many
countries for patients with locally advanced rectal cancer
(LARC) [1-4]. When followed by total mesorectal excision
(TME), the risk of local relapse is 5-10% in patients treated
with 5-fluorouracil (5-FU) and radiotherapy with 50.4 Gy.
A pathological complete response (pCR) with these regi-
mens is achieved in 10-15% of patients with acceptable
toxicities. However, distant metastases occur in about a
third of patients resulting in 10-year survival rates of 60%
[5]. Therefore, there is a need to further improve treatment
approaches to LARC.
A pCR after preoperative RCT is associated with
favourable overall survival in rectal cancer patients and
considered to be an appropriate early endpoint for
evaluation of the effectiveness of intensified RCT-
regimens [6-14]. In four randomized phase III trials
oxaliplatin was added to 5-FU based preoperative RCT,
but results will require further discussion [15-18]. The
German CAO/ARO/AIO-04 trial which added oxaliplatin
to 5-FU showed a small but significant improvement in
pCR rate (17% vs. 13%). It has to be shown, whether these
results further impact on decreased rates of local recur-
rences or distant metastases.
Bevacizumab (Avastin
W; Genentech, Inc., South San
Francisco, CA, USA), is a humanized monoclonal antibody
against vascular endothelial growth factor A (VEGF-A), a
critical and essential factor of angiogenesis, that pro-
motes new vessel formations in tumors [19,20]. In meta-
static colorectal cancer, chemotherapy combined with
bevacizumab improves progression free and overall sur-
vival in 1
st and 2
nd line treatment. Preclinical data suggest
that incorporating bevacizumab into preoperative RCT
might improve the efficacy of radiotherapy [21].
Bevacizumab is associated with mechanism-based ad-
verse events, for example, hypertension, gastrointestinal
perforation, serious bleeding, thromboembolic events
and wound-healing complications. Trials reported an
increased risk of complications across all tumor types,
which might be related to the VEGF blocking mechan-
ism raising the question if the anti-VEGF-containing
regimen may increase wound complications in the
preoperative setting [22].
We initiated this prospective trial to evaluate the effi-
cacy, safety and tolerability of adding bevacizumab to
preoperative radiotherapy with a regimen of concurrent
capecitabine and oxaliplatin (BevXelOx-RT) in patients
with LARC. The pCR rate was the primary endpoint of
this phase II study.
Patients and methods
The study was conducted according to the principles of
the Declaration of Helsinki and to good clinical practice
guidelines. The Ethics Committee, University of Luebeck
(No. 07–197) and all local review boards of the partici-
pating institutions approved this study. Each patient
gave written informed consent before being accrued.
Eligibility criteria
The eligibility criteria included histopathologically con-
firmed rectal cancer with the inferior margin within
16 cm from the anal verge, cT3-4 disease and/or positive
perirectal lymph nodes without evidence of synchronous
metastatic disease; however, a single resectable liver me-
tastasis was not an exclusion criterion. Staging required
endorectal ultrasonography and computed tomography
of the pelvis, whereas the use of magnetic resonance
imaging for staging was encouraged. Further inclusion
criteria included Eastern Cooperative Oncology Group
performance status <2, adequate renal, hepatic and
hematologic function (creatinine clearance >50 mL/min,
total bilirubin concentration ≤ 2.0 mg/dL, liver transami-
nases and alkaline phosphatase concentration less than
three times the upper normal limit and neutrophils >2.5
x1 0
9/L). Patients were excluded if radiotherapy to the
pelvic region or chemotherapy had previously been ad-
ministered. Patients suffering from the following condi-
tions were also ineligible: inflammatory bowel disease,
malabsorption syndrome, history of other cancer, previ-
ous history of cardiac arrhythmia or coronary heart
disease, peripheral neuropathy and psychiatric disorders
or psychological disabilities thought to adversely affect
treatment compliance. Pregnant or lactating patients
and woman with childbearing potential who had lacked
effective contraception were excluded.
Pretreatment evaluation
Pretreatment evaluation included a complete history and
physical examination, biopsy, digital examination, rigid
rectoscopy, colonoscopy, endorectal ultrasound, com-
puted tomography of the pelvis and abdomen and chest
X-ray, ECG. Complete laboratory tests included a full
blood count, blood electrolytes, creatinine, urea, liver
transaminases, alkaline phosphatase, total bilirubin.
Radiotherapy
Radiotherapy was delivered by a linear accelerator with a
minimal energy of 6 MeV through a three- or four-field
box technique to the primary tumor and mesorectal,
presacral and regional lymph nodes up to the level of
the fifth lumbal vertebra. The anal sphincter complex
was included for low-lying tumors (< 6 cm from the anal
verge). The dose was prescribed to a reference point
according to ICRU 50 with the 95% reference-isodose
covering the planning target volume. All patients
received a total dose of 50.4 Gy, with daily fractions of
1.8 Gy on 5 days per week.
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During preoperative therapy, bevacizumab was adminis-
tered with 5 mg/kg body weight on days 1, 15 and 29.
Capecitabine was administered at a fixed dose of
825 mg/m
2 twice daily (30 min after breakfast and din-
ner) on days 1 to 14 and 22 to 35 of radiotherapy, and
oxaliplatin as a 2-h infusion on days 1, 8, 22 and 29 at a
dose of 50 mg/m, according to a schedule previously
used in 2 phase II trials of our group [23-25] (Figure 1).
During treatment, patients were evaluated weekly
regarding history, clinical examination, blood count, and
biochemistry. Toxicities were assessed by National Can-
cer Institute Common Toxicity Criteria (NCI-CTC), ver-
sion 3.0. We did not modify the radiotherapy schedule
for grade≤ 2 toxicities unless the severity worsened.
Image-guided re-evaluation of the primary tumor was
performed four weeks after the completion of preopera-
tive treatment.
Surgery and pathology
Four to six weeks after completion of radiochemother-
apy with bevacizumab, TME was performed according
to a standardized technique. If adjacent organs were
involved intraoperatively, surgery was extended to partial
or total resection of those adjacent pelvic organs. Central
quality control of the surgery was not performed.
Pathologic complete response (pCR) was defined as the
complete disappearance of viable tumor cells in the pri-
mary tumor and lymph nodes (ypT0N0). Histological re-
gression was semiquantitatively determined according to a
5-point regression grading system established by Dworak
by the local pathologist (no centralized analysis) [26].
Adjuvant chemotherapy
Adjuvant chemotherapy was not mandatory by this
protocol but it was recommended as monotherapy with
capecitabine 1250 mg/m
2 twice daily on days 1 to 14,
repetition from day 22 for a total of 4 cycles.
Study design, endpoints and statistical analysis
A prospective single-stage design according to Fleming
was selected. The primary endpoint of the phase II study
after preoperative BevXelOx-RT was pCR rate. Data of
phase II trials with capecitabine, oxaliplatin and radio-
therapy suggests pCR rates of 15-20%. We aimed to
evaluate whether a 25% pCR rate could be achieved by
adding bevacizumab to standard preoperative radioche-
motherapy. A pCR rate of ≤ 15% was considered futile.
With a sample size of 70 patients, the risk of erroneously
claiming a major increase in activity despite a true pCR
rate ≤ 15% (type I error) amounted to 10%, with a type II
error probability of mistakenly rejecting BevXelOx-RT in
the case of truly promising activity set of 20% correspond-
ing to a power of 80% in a one-sided chi-square test. The
secondary endpoints included radiographic response,
pathologic downstaging, tumor regression grading, rates
of sphincter-sparing surgery, toxicity (particularly postop-
erative surgical complications, risk of bowel perforation,
wound healing complications and bleeding), rates of R0
resection and feasibility.
Results
Patient characteristics
A total of 70 patients were enrolled into the study at 6
investigation centers from July 2008 through February
50.4 Gy
Radiotherapy:
28 x 1.8 Gy
Chemotherapy:
Capecitabine
(1650 mg/m
2/d)
Oxaliplatin
(50 mg/m
2/d)
Bevacizumab
(5 mg/kg/d)
Weeks
d 1
d 1 - 14 
d 8 d 22 d 29
Histopathologically confirmed rectal cancer
123 456
d 22 - 35
d 1 d 15 d 29
Figure 1 Overview of the study design and treatment schedule.
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analysis because of serious uncontrolled physical or
psychological disabilities. Therefore the intent-to-treat
population is based on 69 patients. For 4 of these patients,
the primary endpoint was not evaluated. The per-protocol
-population consisted of 58 patients, who received the
complete RCT. Safety analyses were performed within the
69 patients of the safety-population receiving at least on
treatment application of the RCT. ITT- and safety popula-
tion were not different from composition. The median age
was 61 years (range 39–89), at initial diagnosis of the
locally advanced rectal cancer 84% of patients showed
clinical stage T3, 62% of patients had nodal involvement
and 83% of patients were M0. The patient characteristics
are listed in Table 1.
Toxicity and dose modification
A total of 58 patients received preoperative BevXelOx-RT
at the recommended dose level. Tables 2 and 3 show the
frequencies and grades of the treatment-related toxicity.
Adverse events were grouped whether they occured
preoperatively and postoperatively. For both periods, 17
and 18 severe adverse events were reported, respectively.
No perioperative death was documented.
The most frequent adverse event reported in the period
up to one week after radiotherapy was in 31 patients
Table 1 Baseline characteristics (n= 69)
Characteristics Value
Age, years
Median age 61.0
Range 39–89
Gender, n (%)
Male 47 (68)
Female 22 (32)
ECOG performance status, n (%)
0 47 (78)
1 13 (22)
TN clinical stage, n (%)
T2N1-N2 2 (3)
T3N0 12 (17)
T3N1-N2 44 (64)
T4N0 3 (4)
T4N1-N2 4 (6)
M clinical stage, n (%)
Mx 10 (14)
M0 57 (83)
M1 2 (3)
Tumor distance from anal verge, n (%)
Mean±SD (cm) 5.92±3.68
Upper third (≥12 cm) 20 (33)
Middle third (6–12 cm) 26 (42)
Lower third (≤6 cm) 27 (43)
Abbreviation: ECOG= Eastern Cooperative Oncology Group.
Data presented as number of patients, with percentages in parentheses.
Table 2 Acute toxicities occurring during preoperative
treatment
Toxicities Patients, n (%)
Grade 1 Grade 2 Grade 2 Grade 2
Hematological
Anemia 2(3) 1(1) - -
Leucopenia 7(10) 5(7) 1(1) -
Thrombocytopenia 3(4) 1(1) - -
Non-hematological
Diarrhea 17(25) 8(12) 2(3) 1(1)
Nausea 17(25) 5(7) - 1(1)
Fatigue 15(22) 2(3) - -
Paresthesia 13(19) 2(3) - -
Obstipation 2(3) - 1(1) -
Anal abscess - - 1(1) -
Anaphylactic reaction - - 1(1) -
Hypertension - 5(7) - -
Palmar-plantar
erythrodysesthesia
8(12) - - -
Pain 5(7) 2(3) - -
Table 3 Postoperative acute toxicities
Toxicities Patients, n (%)
Grade 1 Grade 2 Grade 3 Grade 4
Hematological
Leucopenia 2(3) 1(1) 1(1) -
Non-hematological
Palmar-plantar
erythrodysesthesia
14(20) 2(3) 1(1) -
Fatigue 11(16) 2(3) 1(1) -
Diarrhea 6(9) 2(3) 3(4) -
Paresthesia 5(7) 5(7) - -
Ileus - - - 1(1)
Nausea 2(3) 1(1) 1(1) -
Proctitis - - 1(1) -
Abdominal pain - - 1(1) -
Anal fistula - - 1(1) -
Pelvic abscess - - 1(1) -
Sensory neuropathy 1(1) 4(6) 1(1) -
Somnolence - - 1(1) -
Delayed woundhealing - - 1(1) -
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rhea, followed by nausea in 22 (32%) of patients, fatigue in
17 (32%), paresthesia in 15 (22%) and leucopenia in 13
(19%) patients. Any grade 3 or 4 toxicities were experi-
enced by 6 and 2 patients, respectively: grade 4 toxicities
included diarrhea and nausea and were restricted in one
patient (1.4%), respectively. Grade 3 diarrhea occurred in
2 patients (3%) and grade 3 obstipation, anal abscess, ana-
phylactic reaction, leucopenia and neutropenia occurred
in one patient (1.4%), respectively (Table 2).
The postoperative period was defined as the interval
between surgery and the final examination four weeks
after surgery. During this period, 43 (27%) adverse events
occurred in 26 patients within the gastrointestinal tract
system. The most common adverse event was the palmar-
plantar erythrodysesthesia in 17 (25%) patients followed
by fatigue in 14 (20%), diarrhea in 11 (16%) and
paresthesia in 10 (14%) patients. The only grade 4 toxicity
was ileus in one patient. Grade 3 toxicity occurred in 10
patients: diarrhea in 3 patients (4%) and nausea, proctitis,
abdominal pain, anal fistula, pelvic abscess, sensoric neur-
opathy, somnolence, palmar-plantar erythrodysesthesia,
fatigue, pain, delayed woundhealing and leucopenia in one
patient (1.4%), respectively. Furthermore, we observed
thrombosis in 3 patients (4%) and one deep vein throm-
bosis in one patient (1.4%) without stating grade (Table 3).
Among 69 patients commencing treatment, dose
reduction or treatment discontinuations was necessary
in 11 patients. 3 patients did not proceed to surgery
(one patient with lost of follow up before surgery, one
patient with progressive disease during preoperative
treatment and exclusion from the study due to the
protocol, one patient refused surgery), for one additional
patient the pathological review was not assessable. For
these 4 patients, the primary endpoint was not evaluated.
In 9 patients, interruption of therapy was observed.
The mean relative dose intensity was high for beva-
cizumab (98.6%), oxaliplatin (97.8%) and radiotherapy
(98.4%). For capecitabine being administered at a fixed
dose of 825 mg/m
2 twice daily on days 1 to 14 and 22 to
35 - according to the flat dosing scheme patients received
2000 mg/m
2 to 3000 mg/m
2.6 2o f6 9p a t i e n t s( 9 0 % )r e -
ceived 100% of the recommended capecitabine, with dose
reduction of capecitabine being observed in 7 patients.
Efficacy
66 of 69 patients underwent surgery and achieved
R0-resection (95.7%, Table 4). A pCR defined as ypT0N0
was observed in 12 of 69 patients for the intent-to-treat
population (17.4%; 95% confidence interval, 10.4%-
26.6%). Pathological downstaging (ypT <cT and ypN≤
cN) was noted in 31 patients (44.9%, Table 5).
Pathohistology information was available in 56 out of
66 patients (on treatment cohort). For 10 patients
adequate data were not assessable. A complete regres-
sion of the tumor defined as ypT0 was documented in
11 patients (15.9% of the ITT cohort; 90% confidence
interval, 9.2%-25.0%; 19.6% of the treatment cohort). 22
more patients (31.9% and 39.2% of the ITT cohort and
on treatment cohort, respectively) showed good tumor
regression (>50% of the tumor mass), moderate (n= 15,
21.7%), or minimal (n =8, 11.6%) tumor regression,
whereas no pathohistological response was observed in 3
patients (4.3%).
39 patients (56.6%) had no evidence for nodal involve-
ment defined as pN0, 4 patients (5.8%) showed a good
nodal regression, moderate (n =2, 2.8%), minimal (n =1,
1.4%) and no regression was noted in 4 patients (5.8%).
The sphincter preserving rate was 68.1% (47 of 69 pa-
tients). A temporary stoma was used in 13 patients (19.7%).
In total, 25 patients (36.2%) developed postoperative
complications of any grade including one gastrointestinal
perforation in one patient (1.4%), wound-healing problems
in 7 patients (9.8%) and bleedings in 2 patients (2.8%).
Follow up evaluation was limited to 6 months after
initiation. Disease progression occurred in four patients.
Two patients developed distant metastases (one lung,
one liver) two months after initiation. For the third pa-
tient with progressive disease one month after initiation
of therapy, adequate data regarding localization were not
available. One patient with synchronous distant metasta-
ses (liver, lymph nodes) achieved tumor response (partial
remission) with incomplete information of local lesion.
6 months after initiation all patients were alive.
Discussion
We conducted this phase II trial as a multimodal regi-
men for patients with locally advanced rectal cancer,
Table 4 Surgical procedures and resection status after
preoperative BevXelOx-RT
Characteristics Value
Type of surgery, n (%)
Low anterior resection 28
Abdominoperineal exstirpation 19
Total mesorectal excision 13
Partial mesorectal excision 1
Mesorectal excision 1
Laparoscopic assisted rectal resection 1
Rectal exstirpation 1
Sigma-rectal exstirpation 1
Rectal resection with pouch 1
Resection status
§
R0 66 (95.7)
Data presented as number of patients, with percentages in parentheses.
§ Refers to the primary tumor, 66 of 69 patients who underwent surgery.
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tered chemotherapy with capecitabine, oxaliplatin and
bevacizumab. This report summarizes the results of 69
patients and to the best of our knowledge, this is the lar-
gest trial in the multimodality therapy with bevacizumab-
containing radiochemotherapy of rectal cancer patients in
the preoperative setting.
Regarding the primary endpoint of our phase II study,
we failed to demonstrate a pCR rate considered to be
“interesting”. The pCR rate of less than 18% was in the
range of other reports investigating regimen with
capecitabine alone or plus oxaliplatin in preoperative
radiochemotherapy. Pathological downstaging (ypT<cT
and ypN≤cN) was observed in 31 of 69 patients (44.9%).
Bevacizumab containing preoperative radiochemother-
apy in rectal cancer has been investigated in a number
of trials and appears to be safe and feasible with benefi-
cial effects on vascular normalization, and promising
response rates in smaller studies [27-33]. Velenik et al.
[27] recently reported the efficacy of the addition of
bevacizumab to capecitabine-RT in 61 patients with
LARC. In this investigation, 13.3% achieved a pCR, and
T-, N- and overall downstaging rates were 46.7%, 65.0%
and 75.0%, respectively. Kennecke et al. [28] reported a
similar pCR rate of 18.4% after a further triple treatment
with bevacizumab, capecitabine, oxaliplatin and radiation.
In 9 patients (23.7%) a complete regression of the tumor
(ypT0) was documented including two patients with nodal
metastases. Similarly, five of 25 patients (20%) had a pCR
in the trial conducted by Dipetrillo et al. [29] using
bevacizumab, oxaliplatin, 5-fluorouracil and radiation for
rectal cancer. However, in this small study two cycles of
induction mFOLFOX6 and bevacizumab were adminis-
tered before concurrent bevacizumab, oxaliplatin, con-
tinuous infusion 5-fluoruracil and radiation.
Several phase II and III trials have shown that the com-
bination of preoperative radiation with 5-FU/capecitabine
and oxaliplatin shows moderately high rates of histopatho-
logical eradication of the tumor. Data of phase II trials
suggested a pCR rate up to 20%, whereas results of phase
III trials showed either no or only modest improvements
with respect to the pCR rates [15-18,34,35]: the Italian
STAR-01 study [16] as well as the US NSABP R-04 trial
[17] and the French ACCORD study [18] did not show a
significant increased rate of pCR´s, and in the German
phase III trial, a small but statistically significant incre-
ment was documented [15].
The potential role of preoperative bevacizumab in
combination with oxaliplatin remains still unclear. Pre-
operative bevacizumab could potentially impact the
histopathological eradication alone or in combination
with 5-FU or capecitabine since unprecedented synergis-
tic or additive interaction between antiangiogenic and
cytotoxic therapies initially has been reported in preclin-
ical settings as well as in early phase I/II trials in terms
of administration of bevacizumab alone or combined
with 5-FU [21].
The addition of bevacizumab to radiochemotherapy
with capecitabine and oxaliplatin did not lead to in-
creased perioperative morbidity or mortality. The ob-
served complications regarding quantity and kind of
intervention after surgical treatment were within the
expected range, without evidence of a modified spectrum
of complications. In particular, we did not observe an in-
creased number of bleeding complications, perioperative
complications including anastomotic insufficiency or
thromboembolic events. The most frequent adverse
events reported in the period of BevXelOx-RT were
chemotherapy-related, as diarrhea, nausea, fatigue, and
paresthesia. In the postoperative period including surgery
adverse events were mainly related to gastrointestinal tract
system but also to pelvic abscess and delayed wound
healing. No treatment related death was observed. With
regard to perioperative complications in published
bevacizumab-containing approaches in rectal cancer
[29,30,32] we can conclude that bevacizumab does not
increase the perioperative complication rate.
Potential benefits of bevacizumab may result in two
different ways: to improve local control rate, which may
be mirrored by the increased pathohistological response,
Table 5 Postoperative pathological TNM stages compared with pretreatment clinical stages (n =69)
Pathologic stage
Baseline stage ypTis ypT0 ypT1 ypT2 ypT3 ypT4 ypTmissing ypN0 ypN1 yPN2 ypNmissing
T1 (n= 1) 1
T2 (n= 3) 2 1
T3 (n= 57) 1 12 3 14 24 2 1
T4 (n= 5) 1 2 2
N0 (n= 15) 13 1 1
N1 (n= 41) 28 6 6 1
N2 (n= 8) 521
Nx (n=2) 11
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this single arm phase II trial, the addition of bevacizumab
to a complex multimodal regimen of a combination
chemotherapy regimen and conventionally fractionated
radiotherapy did not result in a clinically relevant
increased pathohistologic response (namely pCR rate)
compared to other reports. However, this somehow stands
in contrast to the benefit of bevacizumab added to similar
chemotherapy (FOLFOX or XELOX) regimens in meta-
static colorectal cancer, when used as neoadjuvant
therapy for liver metastases: Here, four phase II trials
including more than 300 patients have reported
higher pathohistologic response, including pCR rates
[36-39]. Interestingly, the potential benefit of adding
bevacizumab to standard chemotherapy was also seen in
breast cancer, where even randomized trials reported
increased pathologic complete response rates by more
than 6% (34.5% vs. 28.2%) and overall clinical complete
response rates by up to 8% (87.4% vs. 79.6%) [40,41].
It is not understood why this effect was not observed
here; despite the preclinical and early clinical findings
that bevacizumab may impact the pCR trials in terms of
administration as monotherapy or in combination with
fluoropyrimidines alone [21]. The potential benefit of
adding bevacizumab to FOLFOX or XELOX in order
to prevent patients with LARC from distant failure is
questionable since bevacizumab in combination with
oxaliplatin-based adjuvant therapy in patients with
resected stage III or high-risk stage II colon carcin-
oma did not result in a clinical benefit [42,43].
Long term effects of this combined therapy regimen
can not be judged by this trial and we also recognize the
still ongoing discussion regarding the problem of using
pCR as surrogate parameter in rectal cancer. Stage,
tumor specimen, quality of pathologic analysis and the
time period between therapy and surgery are considered
to be key criterion for the impact on pCR. Several trials
chosing pCR as a primary endpoint achieved lower rates
of complete responses compared with historical data
resulting from quality improvement of pathohistologic
analysis [44]. The randomized phase II trial of Dewdney
et al. demonstrated in KRAS/BRAF wild-type rectal can-
cer patients a significantly improved overall survival of
the cetuximab arm without an increase of the pCR rate
suggesting a possible benefit from systemic approaches
before local therapy based on some not yet clearly
understood biologic activity in this setting [44]. These
effects regarding the long-term outcomes may also arise
in the actual investigation.
However, at this time, long-term follow up results on
survival and also on local control after preoperative radio-
chemotherapy with bevacizumab are needed in order to
determine the potential impact of adding bevacizumab to
preoperative standard treatment in patients with locally
advanced rectal cancer. Furthermore, randomized trials
are ongoing, in order to investigate the benefit of
bevacizumab in addition to chemotherapy alone (without
radiotherapy) in LARC.
Conclusion
The results of our present clinical trial confirm that
preoperative bevacizumab-based radiochemotherapy is
feasible and well tolerated in LARC. However, the in-
corporation of bevacizumab into a combination regi-
men with 5-FU and oxaliplatin seems not to increase
pathohistological response rates.
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